Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
January 12, 2012
Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C
July 21, 2011
Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial
March 8, 2011
Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial
Evry (France), March 8th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA) today… (read more)
January 5, 2011
Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston
December 14, 2010
bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy
February 24, 2010
Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)
February 23, 2010
Genethon appoints biopharma industry expert Frédéric Revah as Chief Executive
February 20, 2009
Gene therapy: Production of the first batch of HIV-derived vectors in Europe for use in a human clinical trial
Genethon, the laboratory created and funded by the AFM (French Association against Myopathies) using donations from Téléthon, today announced that it has produced, controlled and released a batch of lentiviral vectors derived from the human immunodeficiency (HIV) virus for a gene therapy trial in humans in a rare immune deficiency. The… (read more)
February 12, 2008
